Brain Scientific, Inc. (BRSF) financial statements (2021 and earlier)

Company profile

Business Address 125 WILBUR PLACE, SUITE 170
BOHEMIA, NY 11716
State of Incorp. NV
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 26116400
Cash and cash equivalents 26116400
Receivables 6   
Inventory, net of allowances, customer advances and progress billings   23
Inventory   23
Prepaid expense 1   
Other undisclosed current assets 2215  
Total current assets: 28917824
Noncurrent Assets
Property, plant and equipment 22  
Total noncurrent assets: 22  
TOTAL ASSETS: 29118024
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 299140196
Accounts payable   196
Other undisclosed accounts payable and accrued liabilities 299140  
Debt 499 7035
Due to related parties 323508643
Other liabilities 65  
Other undisclosed current liabilities 5932  
Total current liabilities: 1,18722717584
Noncurrent Liabilities
Liabilities, other than long-term debt  7  
Other liabilities  7  
Total noncurrent liabilities:  7  
Total liabilities: 1,18723417584
Stockholders' equity
Stockholders' equity attributable to parent (896)(54)(173)(81)
Common stock 19191010
Additional paid in capital 2,7572,59500
Accumulated other comprehensive income 0   
Accumulated deficit (3,672)(2,668)(183)(91)
Total stockholders' equity: (896)(54)(173)(81)
TOTAL LIABILITIES AND EQUITY: 29118024

Income statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 489587 
Other income 218  
Cost of revenue
(Cost of Goods and Services Sold)
 (387)(34)(1) 
Gross profit: 102246 
Operating expenses (1,072)(1,309)(92)(90)
Operating loss: (970)(1,285)(86)(90)
Nonoperating expense (31)(141)(6)(0)
Debt instrument, convertible, beneficial conversion feature  123  
Interest and debt expense (33)(159)(6)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes 3315960
Loss from continuing operations before income taxes: (1,002)(1,426)(92)(91)
Income tax expense (2)   
Net loss available to common stockholders, diluted: (1,004)(1,426)(92)(91)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (1,004)(1,426)(92)(91)
Comprehensive loss: (1,004)(1,426)(92)(91)
Other undisclosed comprehensive income, net of tax, attributable to parent 0   
Comprehensive loss, net of tax, attributable to parent: (1,003)(1,426)(92)(91)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: